2024 Q2 Form 10-Q Financial Statement
#000095017024055655 Filed on May 08, 2024
Income Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
Revenue | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $21.71M | $22.84M |
YoY Change | 48.3% | 72.7% |
% of Gross Profit | ||
Research & Development | $134.9M | $118.0M |
YoY Change | 37.71% | 71.18% |
% of Gross Profit | ||
Depreciation & Amortization | $1.600M | $1.500M |
YoY Change | 33.33% | 24.48% |
% of Gross Profit | ||
Operating Expenses | $156.6M | $140.9M |
YoY Change | 39.09% | 71.42% |
Operating Profit | -$156.6M | -$140.9M |
YoY Change | 43.98% | 87.42% |
Interest Expense | $21.49M | $23.76M |
YoY Change | 104.66% | 236.59% |
% of Operating Profit | ||
Other Income/Expense, Net | $23.41M | $24.86M |
YoY Change | 122.97% | 252.12% |
Pretax Income | -$133.2M | -$116.0M |
YoY Change | 35.54% | 70.35% |
Income Tax | $0.00 | $0.00 |
% Of Pretax Income | ||
Net Earnings | -$133.2M | -$116.0M |
YoY Change | 35.54% | 70.35% |
Net Earnings / Revenue | ||
Basic Earnings Per Share | -$0.81 | -$0.70 |
Diluted Earnings Per Share | -$0.81 | -$0.70 |
COMMON SHARES | ||
Basic Shares Outstanding | 165.0M | 164.7M |
Diluted Shares Outstanding | 165.1M | 164.7M |
Balance Sheet
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $1.591B | $1.704B |
YoY Change | 74.9% | 87.24% |
Cash & Equivalents | $275.7M | $288.4M |
Short-Term Investments | $1.315B | $1.415B |
Other Short-Term Assets | $34.02M | $25.66M |
YoY Change | 237.02% | 186.47% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $0.00 | $0.00 |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $1.625B | $1.729B |
YoY Change | 76.2% | 87.4% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $25.28M | $23.70M |
YoY Change | 28.23% | 27.84% |
Goodwill | $14.61M | $14.61M |
YoY Change | 0.0% | 0.0% |
Intangibles | $57.21M | $57.47M |
YoY Change | -1.83% | -1.82% |
Long-Term Investments | ||
YoY Change | ||
Other Assets | $8.274M | $4.159M |
YoY Change | 207.47% | 50.04% |
Total Long-Term Assets | $183.7M | $179.2M |
YoY Change | 21.17% | 19.05% |
TOTAL ASSETS | ||
Total Short-Term Assets | $1.625B | $1.729B |
Total Long-Term Assets | $183.7M | $179.2M |
Total Assets | $1.808B | $1.908B |
YoY Change | 68.43% | 77.81% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $29.32M | $32.38M |
YoY Change | -1.56% | 62.61% |
Accrued Expenses | $75.36M | $60.60M |
YoY Change | 57.24% | 84.24% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $105.3M | $93.72M |
YoY Change | 34.94% | 71.54% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $656.0K | $3.040M |
YoY Change | 160.32% | 79.46% |
Total Long-Term Liabilities | $656.0K | $3.040M |
YoY Change | 160.32% | 79.46% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $105.3M | $93.72M |
Total Long-Term Liabilities | $656.0K | $3.040M |
Total Liabilities | $189.6M | $182.9M |
YoY Change | 32.7% | 51.12% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.400B | -$1.300B |
YoY Change | 61.35% | 68.96% |
Common Stock | $3.008B | $2.980B |
YoY Change | 67.11% | 73.06% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $1.619B | $1.725B |
YoY Change | ||
Total Liabilities & Shareholders Equity | $1.808B | $1.908B |
YoY Change | 68.43% | 77.81% |
Cashflow Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$133.2M | -$116.0M |
YoY Change | 35.54% | 70.35% |
Depreciation, Depletion And Amortization | $1.600M | $1.500M |
YoY Change | 33.33% | 24.48% |
Cash From Operating Activities | -$128.2M | -$160.6M |
YoY Change | 90.95% | 157.34% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $2.399M | $3.167M |
YoY Change | 114.39% | 80.15% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $110.3M | -$244.8M |
YoY Change | -360.09% | -4354.41% |
Cash From Investing Activities | $107.9M | -$248.0M |
YoY Change | -347.9% | -6305.36% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 7.504M | 810.0K |
YoY Change | -88.39% | -99.75% |
NET CHANGE | ||
Cash From Operating Activities | -128.2M | -160.6M |
Cash From Investing Activities | 107.9M | -248.0M |
Cash From Financing Activities | 7.504M | 810.0K |
Net Change In Cash | -12.72M | -407.7M |
YoY Change | -72.37% | -253.39% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$128.2M | -$160.6M |
Capital Expenditures | $2.399M | $3.167M |
Free Cash Flow | -$130.6M | -$163.7M |
YoY Change | 91.33% | 155.23% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2024Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2024Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001628171 | |
CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2024Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://www.revolutionmedicines.com/20240331#CollaborationRevenueMember | |
CY2023Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://www.revolutionmedicines.com/20240331#CollaborationRevenueMember | |
CY2024Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2024Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2024Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | |
CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2024Q1 | dei |
Entity File Number
EntityFileNumber
|
001-39219 | |
CY2024Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
Revolution Medicines, Inc. | |
CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-2029180 | |
CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
700 Saginaw Drive | |
CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Redwood City | |
CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94063 | |
CY2024Q1 | dei |
City Area Code
CityAreaCode
|
650 | |
CY2024Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
481-6801 | |
CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
164986227 | |
CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
288432000 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
696148000 | |
CY2024Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1415108000 | |
CY2023Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1156807000 | |
CY2024Q1 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
0 | |
CY2023Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
1254000 | |
CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
25662000 | |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
25072000 | |
CY2024Q1 | us-gaap |
Assets Current
AssetsCurrent
|
1729202000 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1879281000 | |
CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
23697000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
22865000 | |
CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
76193000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
77149000 | |
CY2024Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
57472000 | |
CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
57739000 | |
CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
14608000 | |
CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
14608000 | |
CY2024Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
3031000 | |
CY2023Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
3031000 | |
CY2024Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
4159000 | |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
7032000 | |
CY2024Q1 | us-gaap |
Assets
Assets
|
1908362000 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
2061705000 | |
CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
32379000 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
61788000 | |
CY2024Q1 | rvmd |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
53175000 | |
CY2023Q4 | rvmd |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
74694000 | |
CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8169000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7369000 | |
CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
93723000 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
143851000 | |
CY2024Q1 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
3115000 | |
CY2023Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
3115000 | |
CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
79860000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
80575000 | |
CY2024Q1 | rvmd |
Warrant Liability
WarrantLiability
|
3157000 | |
CY2023Q4 | rvmd |
Warrant Liability
WarrantLiability
|
6512000 | |
CY2024Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
3040000 | |
CY2023Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1458000 | |
CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
182895000 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
235511000 | |
CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
170473067 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
170234594 | |
CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
164913014 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
164674594 | |
CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
16000 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
16000 | |
CY2024Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2980360000 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2963342000 | |
CY2024Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1198000 | |
CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
544000 | |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1253711000 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1137708000 | |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1725467000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1826194000 | |
CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1908362000 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
2061705000 | |
CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
7014000 | |
CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
7014000 | |
CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
118021000 | |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
68947000 | |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22838000 | |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13224000 | |
CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
140859000 | |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
82171000 | |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-140859000 | |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-75157000 | |
CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
23760000 | |
CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
7059000 | |
CY2024Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
2809000 | |
CY2023Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
0 | |
CY2024Q1 | rvmd |
Change In Fair Value Of Warrant Liability And Contingent Earn Out Shares
ChangeInFairValueOfWarrantLiabilityAndContingentEarnOutShares
|
3905000 | |
CY2023Q1 | rvmd |
Change In Fair Value Of Warrant Liability And Contingent Earn Out Shares
ChangeInFairValueOfWarrantLiabilityAndContingentEarnOutShares
|
0 | |
CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
24856000 | |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
7059000 | |
CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-116003000 | |
CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-68098000 | |
CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-116003000 | |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-68098000 | |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.7 | |
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.7 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.72 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.72 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
164729200 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
164729200 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
94831979 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
94831979 | |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-116003000 | |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-68098000 | |
CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1742000 | |
CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1224000 | |
CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-117745000 | |
CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-66874000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1826194000 | |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
810000 | |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
16208000 | |
CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1742000 | |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-116003000 | |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1725467000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
685188000 | |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
499000 | |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9699000 | |
CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1224000 | |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-68098000 | |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
952218000 | |
CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-116003000 | |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-68098000 | |
CY2024Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-73000 | |
CY2023Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-1000 | |
CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
267000 | |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
267000 | |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
16208000 | |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9699000 | |
CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
1540000 | |
CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
1205000 | |
CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-3905000 | |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
15244000 | |
CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
3577000 | |
CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
956000 | |
CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1061000 | |
CY2024Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
2761000 | |
CY2023Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1254000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-678000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
590000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1611000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-28960000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1050000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-21259000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-1752000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | |
CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3025000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
85000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-894000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-125000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-90000 | |
CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
2132000 | |
CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
1393000 | |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-160560000 | |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-62391000 | |
CY2024Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
701681000 | |
CY2023Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
193097000 | |
CY2024Q1 | rvmd |
Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
|
456882000 | |
CY2023Q1 | rvmd |
Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
|
198851000 | |
CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3167000 | |
CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1758000 | |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-247966000 | |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3996000 | |
CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
323706000 | |
CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
810000 | |
CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
499000 | |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
810000 | |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
324205000 | |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-407716000 | |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
265810000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
699179000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
163149000 | |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
291463000 | |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
428959000 | |
CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
288432000 | |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
427222000 | |
CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
3031000 | |
CY2023Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
1737000 | |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
291463000 | |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
428959000 | |
CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1889000 | |
CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
744000 | |
CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | |
CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
286000 | |
CY2024Q1 | rvmd |
Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
|
15000 | |
CY2023Q1 | rvmd |
Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
|
7000 | |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1300000000 | |
CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including the fair value of assets acquired and liabilities assumed and related purchase price allocation, revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, impairment of in-process research and development and developed technologies, the incremental borrowing rate for determining operating lease assets and liabilities, warrant liabilities and stock-based compensation. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span> | |
CY2024Q1 | rvmd |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Warrant Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesWarrantLiability
|
6907000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
|
490000 | |
CY2024Q1 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
1097099000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
860918000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
|
313878000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
|
12084000 | |
CY2024Q1 | rvmd |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash
|
633000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
|
2912000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
|
6893000 | |
CY2024Q1 | rvmd |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses And Other Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities
|
30506000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
1153026000 | |
CY2024Q1 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
1097099000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
1153026000 | |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
|
55927000 | |
CY2024Q1 | rvmd |
Transaction Costs
TransactionCosts
|
20700000 | |
CY2024Q1 | rvmd |
Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
|
0 | |
CY2023Q4 | rvmd |
Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
|
0 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
1704706000 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
171000 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1369000 | |
CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1703508000 | |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
1852189000 | |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1102000 | |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
558000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1852733000 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
1704706000 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
171000 | |
CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1369000 | |
CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1703508000 | |
CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
42576000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
40559000 | |
CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
18879000 | |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
17694000 | |
CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
23697000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
22865000 | |
CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
1500000 | |
CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
1200000 | |
CY2024Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
9795000 | |
CY2023Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
23613000 | |
CY2024Q1 | rvmd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
40585000 | |
CY2023Q4 | rvmd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
45003000 | |
CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2051000 | |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2182000 | |
CY2024Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
744000 | |
CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3896000 | |
CY2024Q1 | rvmd |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
53175000 | |
CY2023Q4 | rvmd |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
74694000 | |
CY2024Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
55800000 | |
CY2024Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
55800000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
7480000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5808000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1672000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P1Y7M6D | |
CY2024Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
63280000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5808000 | |
CY2024Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
57472000 | |
CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
300000 | |
CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
300000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
802000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
870000 | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1672000 | |
CY2023Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
55800000 | |
CY2023Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
55800000 | |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
7480000 | |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5541000 | |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1939000 | |
CY2023Q4 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P1Y10M24D | |
CY2023Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
63280000 | |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5541000 | |
CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
57739000 | |
CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
14608000 | |
CY2024Q1 | us-gaap |
Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
|
0 | |
CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
14608000 | |
CY2024Q1 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8169000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7369000 | |
CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
79860000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
80575000 | |
CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
88029000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
87944000 | |
CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2798000 | |
CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1818000 | |
CY2024Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
0 | |
CY2023Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
302000 | |
CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
2798000 | |
CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
1516000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
6010000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
10476000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
10843000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
11222000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
11615000 | |
CY2024Q1 | rvmd |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
93486000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
143652000 | |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
55623000 | |
CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
88029000 | |
CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.084 | |
CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P11Y9M18D | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P12Y | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Each share of common stock is entitled to one vote | |
CY2024Q1 | rvmd |
Number Of Voting Rights Per Common Share
NumberOfVotingRightsPerCommonShare
|
1 | |
CY2024Q1 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | |
CY2024Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
31522503 | |
CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
21880211 | |
CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
123200000 | |
CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y29D | |
CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
16208000 | |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9699000 | |
CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-116003000 | |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-68098000 | |
CY2024Q1 | rvmd |
Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
|
164729200 | |
CY2023Q1 | rvmd |
Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
|
94836463 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
0 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
4484 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
164729200 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
164729200 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
94831979 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
94831979 | |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.7 | |
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.7 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.72 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.72 | |
CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
20342614 | |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12677360 |